Association of Psychological Distress With Clinical Outcomes in Patients With Digestive System Cancers
Association of Psychological Distress With Clinical Outcomes in Patients With Digestive System Cancers: A Prospective Cohort Study
This prospective observational cohort study aims to investigate the association between psychological distress and clinical outcomes in patients with digestive system cancers, including pancreatic, gastric, and colorectal cancers.
Approximately 100 adult patients who are scheduled to receive first-line systemic anticancer therapy will be enrolled at Xuanwu Hospital, Capital Medical University. Psychological distress will be assessed using the Distress Thermometer (DT), Hospital Anxiety and Depression Scale (HADS), and 12-item General Health Questionnaire (GHQ-12).
Participants will undergo baseline assessments and follow-up evaluations every three months for up to three years. Clinical information, psychological distress scores, laboratory findings, imaging results, and quality-of-life data will be collected.
The primary outcome is progression-free survival (PFS). Secondary outcomes include overall survival (OS), objective response rate (ORR), and quality of life. The study will evaluate whether psychological distress is associated with cancer prognosis after adjusting for potential confounding factors, including cancer stage, treatment regimen, and nutritional status.
As an observational study, no experimental treatment will be assigned, and all participants will receive standard anticancer treatment according to routine clinical practice.
Studieoversigt
Status
Status
Betingelser
Betingelser
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Kontakter og lokationer
Studiesteder
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 24266
- Xuanwu Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
The study population will consist of approximately 100 adult patients with pathologically confirmed pancreatic, gastric, or colorectal cancer who are scheduled to receive first-line systemic anticancer therapy at the Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China. Eligible patients will be consecutively enrolled according to the predefined inclusion and exclusion criteria. Psychological distress will be assessed at baseline and during follow-up to investigate its association with clinical outcomes, including progression-free survival and overall survival.
Beskrivelse
Inclusion Criteria:
- Patients with pathologically confirmed digestive system cancers, including pancreatic cancer, gastric cancer, or colorectal cancer.
- Male or female patients aged 18 years or older.
- Patients scheduled to receive first-line systemic anticancer therapy, including chemotherapy, targeted therapy, immunotherapy, or combination therapy, with no systemic treatment for the current cancer lesions within 3 months prior to enrollment.
- At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
- Life expectancy of at least 12 weeks, as assessed by the investigator.
- Willing and able to provide written informed consent to participate in the study.
Exclusion Criteria:
- History of another malignancy within the past 3 years or concurrent malignancy.
- Presence of acute or chronic psychiatric disorders, or current treatment with antidepressant or anxiolytic medications.
- Previous treatment in another investigational drug trial.
- Inability to complete psychological assessment questionnaires due to cognitive impairment, language barriers, or other conditions that interfere with questionnaire completion.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-Free Survival (PFS)
Tidsramme: From enrollment to the first documented disease progression or death from any cause, whichever occurs first, assessed up to 3 years.
|
Progression-free survival (PFS) is defined as the time from study enrollment to the first radiologically confirmed disease progression, as assessed by the investigator according to RECIST version 1.1, or death from any cause, whichever occurs first. PFS will be compared between patients with high and low levels of psychological distress. |
From enrollment to the first documented disease progression or death from any cause, whichever occurs first, assessed up to 3 years.
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i det endokrine system
- Neoplasmer efter sted
- Neoplasmer
- Tarmsygdomme
- Gastrointestinale neoplasmer
- Neoplasmer i fordøjelsessystemet
- Sygdomme i fordøjelsessystemet
- Gastrointestinale sygdomme
- Mavesygdomme
- Intestinale neoplasmer
- Endetarmssygdomme
- Neoplasmer i endokrine kirtler
- Pancreassygdomme
- Tyktarmssygdomme
- Neoplasmer i maven
- Kolorektale neoplasmer
- Bugspytkirtel neoplasmer
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- hongyanli3
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .